Atypical motor neurone disease (MND) represents a challenging and expanding group of neurodegenerative disorders involving the upper or lower motor neurones, and rarely both. Neuro-ophthalmological disturbances such as gaze-evoked downbeat nystagmus are extremely rare in the context of typical and atypical MND. Finger extension weakness and downbeat nystagmus motor neurone disease (FEWDON-MND) syndrome has been recently recognised as a distinct syndromic phenotype of MND, with a characteristic clinical picture. We describe a 63-year-old woman with long-standing lower motor neurone involvement of the upper limbs, who on examination had gaze-evoked downbeat nystagmus. After extensive negative investigation for secondary causes of MND and downbeat nystagmus, we diagnosed FEWDON-MND syndrome.
A 40-year-old woman presented with rapidly progressive quadriparesis and severe weight loss. Examination disclosed global amyotrophy, absent deep tendon reflexes and malignant acanthosis nigricans ( Figure). Neurophysiologic studies disclosed pure motor neuronopathy. Paraneoplastic screening with fullbody CT/MRI scan revealed an intravesical mural lesion (Figure) and urethrocystoscopy showed low-grade papillary urothelial carcinoma of the urinary bladder. High-titer serum anti-Hu antibodies were identified. There was marked motor and dermatological improvement after lesion removal, combined with intravenous immunoglobulin and methylprednisolone.Dermatological signs are key diagnostic clues in the suspicion of underlying malignancies 1 , including rarely urological malignancies 2 , in the context of paraneoplastic motor neuronopathy 3,4 .
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.